Document is current
Any future updates will be listed below
-
Authors
Baer, Constance
Kimura, Shunsuke https://orcid.org/0000-0002-2158-467X
Rana, Mitra S. https://orcid.org/0000-0002-0915-8141
Kleist, Andrew B.
Flerlage, Tim
Feith, David J. https://orcid.org/0000-0003-4981-1691
Chockley, Peter https://orcid.org/0000-0002-5181-2696
Walter, Wencke https://orcid.org/0000-0002-5083-9838
Meggendorfer, Manja
Olson, Thomas L.
Cheon, HeeJin
Olson, Kristine C.
Ratan, Aakrosh https://orcid.org/0000-0002-0782-3056
Mueller, Martha-Lena
Foran, James M.
Janke, Laura J.
Qu, Chunxu
Porter, Shaina N.
Pruett-Miller, Shondra M. https://orcid.org/0000-0002-3793-585X
Kalathur, Ravi C. https://orcid.org/0000-0002-4889-8003
Haferlach, Claudia
Kern, Wolfgang
Paietta, Elisabeth
Thomas, Paul G. https://orcid.org/0000-0001-7955-0256
Babu, M. Madan https://orcid.org/0000-0003-0556-6196
Loughran, Thomas P. Jr.
Iacobucci, Ilaria https://orcid.org/0000-0003-2008-1365
Haferlach, Torsten https://orcid.org/0000-0003-0196-2837
Mullighan, Charles G. https://orcid.org/0000-0002-1871-1850
-
Funding
Funding for this research was provided by:
Center for Strategic Scientific Initiatives, National Cancer Institute (P30 CA021765, R35 CA197695, F30CA196040, UG1CA189859, U10CA180820, UG1CA189859, U10CA180820, R01 CA178393, P30 CA044579)
Henry Schueler 41 & 9 Foundation St. Baldrick’s Foundation Robert J. Arceci Innovation Award
Garwood Postdoctoral Fellowship of the Hematological Malignancies Program of the St Jude Children’s Research Hospital Comprehensive Cancer Center
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (T32 GM080202)
U.S. Department of Health & Human Services | NIH | U.S. National Library of Medicine (T32 LM012416)
the Bess Family Charitable Fund, the LGL Leukemia Foundation and a generous anonymous donor
- License Information
-
More Information
Article History
Received: 24 March 2021
Accepted: 21 March 2022
First Online: 5 May 2022
Competing interests
: C.B., W.W., M.M. and M.L.M. are employed by MLL Munich Leukemia Laboratory. C.H., W.K. and T.H. have equity ownership of MLL Munich Leukemia Laboratory. I.I. received honoraria from Amgen and Mission Bio. C.G.M. received research funding from Loxo Oncology, Pfizer and AbbVie, and honoraria from Amgen and Illumina, and holds stock in Amgen. T.P.L. is on the Scientific Advisory Board and has stock options for Keystone Nano, Bioniz Therapeutics and Dren Bio. T.P.L. and D.J.F. received honoraria from Kymera Therapeutics. D.J.F. has research funding from AstraZeneca. There are no conflicts of interest with the work presented in this manuscript. The remaining authors declare no competing interests.
